Litcius/Paper detail

Intravenous arketamine for treatment-resistant depression: open-label pilot study

Gustavo C. Leal, Igor D. Bandeira, Fernanda S. Correia‐Melo, Manuela Telles, Rodrigo P. Mello, Flávia Vieira, Cassio Santos‐Lima, Ana Paula Jesus‐Nunes, Lívia N. F. Guerreiro‐Costa, Roberta Ferrari Marback, Ana Teresa Caliman‐Fontes, Breno Souza‐Marques, Marília Lopes Oliveira Bezerra, Alberto L. Dias-Neto, Samantha S. Silva, Aline S. Sampaio, Gerard Sanacora, Gustavo Turecki, Colleen Loo, Acioly L.T. Lacerda, Lucas C. Quarantini

2020European Archives of Psychiatry and Clinical Neuroscience257 citationsDOIOpen Access PDF

Topics & Concepts

Treatment-resistant depressionAntidepressantKetamineDepression (economics)Rating scaleMedicineAnesthesiaPilot trialClinical trialPsychologyInternal medicineRandomized controlled trialHippocampusEconomicsMacroeconomicsDevelopmental psychologyTreatment of Major DepressionNeurotransmitter Receptor Influence on BehaviorNeuroscience and Neuropharmacology Research
Intravenous arketamine for treatment-resistant depression: open-label pilot study | Litcius